Vendor, Bedford Park, AUS
Vaxine Pty Ltd.
UEI Z9AUC2SNX5A4, CAGE Z0ED5
2 awards and -$535,698 obligated between February 11, 2025 and June 15, 2026, 100% under full and open competition, against 20.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | -$535,698 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93018C00044Definitive Contract, February 11, 2025, Full and Open Competition, 17 offers | National Institutes of Health NiaidNational Institutes of Health | Adjuvant Development ProgramNAICS 541714, PSC AN11 | -$0 |
| 75N93018C00024Definitive Contract, September 23, 2025, Full and Open Competition, 24 offers | National Institutes of Health NiaidNational Institutes of Health | To Advance the Novel H7-Advax Pandemic Vaccine Candidates Through to Phase 1 Clinical Trials Through Delivery to the Government Of: PreliminNAICS 541714, PSC AN12 | -$535,698 |
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic ResearchAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 2 awards